[Cambridge, UK / March 20th, 2019 / Axol Bioscience, a partner in EU-funded MESO-BRAIN project (GA # 713140) has had a new proposal selected for funding by the EU through the FET (Future Emerging Technologies) Launchpad scheme.
The FET Launchpad scheme is available only to existing or recently ended FET projects to encourage development of innovative ideas emerging from a project to be accelerated through separate and dedicated, Launchpad funding.
The COMMER-CELL Launchpad project provides a unique opportunity for the creation of a marketable product stemming from work already programmed within FETOPEN MESO-BRAIN. Co-cultured in vitro cell models have the capacity to retain neuronal maturity and functionality for long periods of time. Such co-cultures, featuring only two or three different cell types have already been demonstrated to be effective models for researching the mechanisms of diseases such as AD and monitoring inflammation response, indicating consistent and reproducible results. As such, complex and consistently reproducible ready-made co-cultures will be promoted to pharmaceutical and biotech companies seeking to use iPSC-derived cells as a basis for building cell-based assays and drug screening based on the validated cells.
As the FETOPEN MESO-BRAIN project already intends to grow the major neuronal cell types, complex, physiologically relevant 2D and 3D co-cultures featuring cortical neurones, astrocytes, interneurons and microglia can be developed within COMMER-CELL and made available for sale. The creation and mass-availability of a four-cell-type co-culture in an easy-to-use and pre-made form could not only allow for improved research into CNS-affecting conditions and drug testing, but also expedite such research by circumventing the need for research institutions and scientific industrial organisation (such as pharmaceutical and biotech companies) to create their own time-consuming cell models.
The proposed COMMER-CELL project harnesses results from MESO-BRAIN to deliver concrete added value by raising the technological maturity of the cells to demonstrator level. The fulfilment of the proposition, based upon anticipated positive feedback from the market, will lead to the commercialisation of an innovation derived from FETOPEN MESO-BRAIN.
MESO-BRAIN partners Aston University, working in conjunction with Laser nanoFAB GmbH, and Institute for Photonic Sciences, ICFO, Barcelona, were also successful in having their own FET Launchpad proposals selected for funding with SCAFFOLD-NEEDs and MAFIn respectively.
About Axol Bioscience
Axol produces high quality human cell products and critical reagents such as media and growth supplements. We have a passion for great science, delivering epic support and innovating future products to help our customers advance faster in their research.
Our expertise includes reprogramming cells to iPSCs and then differentiating to various cell types. We supply differentiated cells derived from healthy donors and patients of specific disease backgrounds. As a service, we also take cells provided by customers (primary or iPSC) and then do the reprogramming (when necessary) and differentiation. Clearly, by offloading the burden of generating cells, your time is freed up to focus on the research. Axol holds the necessary licenses that are required to do iPSC work.
The package wouldn’t be complete without optimized media, coating solutions and other reagents. Our in-house R&D team works hard to improve on existing media and reagents as well as innovate new products for human cell culture. We also supply a growing range of human primary cells; making Axol your first port of call for your human cell culture needs.
For more information, contact:
Headquarters:
Axol Bioscience Ltd Science Village, Chesterford Research Park
Little Chesterford, Cambridge
United Kingdom, CB10 1XL
US Office: Ground Floor, Jean Mayer Administration Building
201 Westboro Road
North Grafton
MA 01536
United States
Phone: +44 (0) 1223 751051
US Toll Free: 1-800-678-AXOL (2965)
Email: info@axolbio.com
